

Key investor information

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.



DWS Biotech


Share class TFC Security code: DWS2UA ISIN: DE000DWS2UA1

Management Company: DWS Investment GmbH, a member of the DWS Group.

Objectives and investment policy

The objective of the investment policy is to achieve sustained capital appreciation relative to the benchmark (NASDAQ Biotechnology). To achieve this, the fund invests mainly in equities of international companies whose revenues or earnings, as reported in the most recent annual report or other suitable documents of the company, were generated primarily from the biotechnology sector, or whose expenditure was primarily on this sector. Equities of issuers from the health care sector may also be added. In that context, the fund management is responsible for selecting the individual investments. The fund is oriented to the benchmark. It does not track it exactly but attempts to exceed its performance and can therefore deviate substantially - both positively and negatively - from the benchmark. The currency of the fund is EUR, the currency of the share class is EUR. Returns and gains are not distributed but are reinvested in the fund. You may request the redemption of shares on each valuation day. The redemption may only be suspended in exceptional cases taking into account your interests as an investor.

Risk and reward profile



The calculation of the risk and reward profile is based on simulated data that cannot be used as a reliable indicator for the future risk profile. This risk indicator is subject to changes; the classification of the fund may change over time and cannot be guaranteed. Even a fund that is classified in the lowest category (category 1) does not represent a completely risk-free investment. The fund is classified in category 7 because its share price may fluctuate very strongly and the likelihood of both losses and gains may therefore be very high. The following risks could be of particular significance for the fund. These risks can impair the performance of the fund and thus impact negatively on the net asset value per unit and on the capital invested by the investor. The unit value may at any time fall below the purchase price paid by the client.

The fund invests its assets in selected regions or sectors. This increases the risk that the fund may be negatively influenced by the economic and political conditions in the respective regions or sectors. The fund invests in equities. Equities are subject to strong price fluctuations and thus also to the risk of price decreases. The fund invests in bonds, the value of which depends on whether the issuer is able to afford its payments. The deterioration of credit quality (ability and willingness to repay) may have an adverse effect on the value of the bond. A more detailed description of risks and other general information can be found under "Risk warnings" in the sales prospectus.

Charges

The costs and fees borne by you are used for the management, administration and custody of the fund, as well as for its distribution and marketing. These costs restrict the potential growth of your investment.

One-off charges taken before or after you invest	
Entry charge	No initial sales charge
Exit charge	No redemption fee
Charges taken from the fund over a year	
Ongoing charge	0,90 %
Charges taken from the fund under certain specific conditions	
Performance fee	0,14 % The performance-based fee corresponds to 25% of the amount by which the performance exceeds that of the NASDAQ Biotech Index, up to a maximum of 4% of the average value of the fund. When calculating the performance-based fee, negative carryforwards from the previous five settlement periods are taken into account. Details can be found in the sales prospectus under "Costs".

The current costs shown here are a cost estimate. The current costs do not include the performance-based fee and the transaction costs. Additional information on costs can be found under "Costs" in the sales prospectus.

Past performance

There is not yet sufficient data available to provide you with useful information regarding earlier performance. The TFC share class of DWS Biotech was launched in 2018.

Practical information

The custodian is State Street Bank International GmbH, Germany. The sales prospectus, annual report and semiannual report are available in the language of this document or in German from DWS Investment GmbH and may be requested free of charge. The current share prices as well as additional information about the fund are available in the language of this document or in German in the "Download" section of the fund on your local DWS website or at www.dws.com. Information on the current remuneration policy of the management company, including a description of how remuneration and benefits are calculated is published on the Internet at www.db.com/cr/en/concrete-compensation-structures.htm. The information will be sent to you in written form free of charge upon request. The fund is subject to German tax law. This may affect how you are taxed on your income from the fund. DWS Investment GmbH may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the sales prospectus. The fund has other share classes. Details of these can be found under "Share classes" in the sales prospectus. This fund is authorized in Germany and is regulated by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht; BaFin). DWS Investment GmbH is authorized in Germany and is regulated by BaFin.

This key investor information is accurate as at 19.02.2019.